Beam Therapeutics Inc. Common Stock
Here’s whether Beam Therapeutics Inc. Common Stock (BEAM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); strong 1-year return of +85.9%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.12% over 10 days). Currently 22.2% off its 52-week high. Score: +1/7.
BEAM is holding above its long-term 200-day MA ($28.16) but has slipped below the 50-day MA ($29.90), pointing to short-term weakness in an otherwise intact trend. An RSI of 67.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +85.9% compares to +20.5% for SPY (beat the market by 65.4%). The current 22.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.